Delivery Order SPE2DB24D2101-SPE2DB25FKNBV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units). The contract was awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, and is structured as a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters...
- The Defense Logistics Agency awarded a $42,270.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units) on August 12, 2025, with an ultimate completion date of September 3, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,519.62 for 120 tablets of Lynparza 100 mg on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside transaction executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,543.70 for 60 tablets of Lynparza 100 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $5,249.67 to supply Lynparza 150 mg tablets (60-count units) under a firm fixed-price contract. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 22, 2025, represents a non-set-aside, competitively awarded procurement. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen Drug Corp's corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $10,499.34 to AmerisourceBergen Drug Corp for 60 tablets of LYNPARZA 150 mg, a pharmaceutical product for oncology treatment. The contract, awarded on August 19, 2025, with an ultimate completion date of September 10, 2025, carries firm fixed pricing and represents a non-set-aside competitive award. Performance will be executed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Lynparza 100 mg tablets in a quantity of 120 units, with a ceiling value of $10,519.62. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by September 10, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $10,567.60 delivery order to AmerisourceBergen Drug Corp for 120 tablets of Lynparza 150 mg, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and reflects a routine pharmaceutical procurement supporting military and federal healthcare operations. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lynparza 150 mg tablets (120 count) valued at $31,702.80. This firm fixed-price delivery order is scheduled for completion by August 25, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $10,543.70 to AmerisourceBergen Drug Corp for 60 tablets of Lynparza 100 mg, a prescription oncology medication. This firm fixed-price delivery order was competitively awarded with no set-aside designation and carries an ultimate completion date of August 25, 2025. The contract was executed on August 4, 2025, with performance to be completed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNBVDelivery Order
The Defense Logistics Agency awarded a $10,519.62 delivery order to AmerisourceBergen Drug Corp for Lynparza 100 mg tablets (120-count units) with a completion date of August 26, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's prime indefinite delivery contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's demonstrated capability to compete successfully for federal pharmaceutical procurement, combined with its extensive portfolio of medical product deliveries across multiple therapeutic domains, positions the company as a critical vendor for Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/5/25 |